XERS News and Press, Xeris Pharmaceuticals Inc. From 03/08/23

Achieved fourth quarter net product revenue of $32.5M representing 52% growth compared to Q4 2021 Achieved full-year net product revenue of $109.3M representing 38% annual growth compared to 2021 on a pro forma basis Ended 2022 with $122.0M in cash, cash equivalents, and short-ter...

Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the C...

Summary Xeris Biopharma expects to report record net product revenue for 2022 thanks to strong growth across their portfolio of approved products. Xeris believes they are still on track to hit its goal of cash flow breakeven by the end of 2023. XERS is trading around $1.25 per share...

Xeris Biopharma, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will hold 1x1 investor meetings and prese...

Headlines Are Fueling Momentum For These Penny Stocks If you’re looking for the best penny stocks to buy, chances are company headlines are a starting point for you. They aren’t hard to find, most brokers will include them front and center on their trading platforms, and if ...

The U.S. Food and Drug Administration (FDA) granted orphan drug exclusivity to Xeris Biopharma's ( NASDAQ: XERS ) Recorlev to treat adult patients with endogenous Cushing's syndrome for whom surgery is not an option or has not been curative. Xeris' unit Xeris ...

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Food and Drug Administration (FDA) granted its subsidiary Xer...

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris’ Chairman and CEO, will pres...

Xeris Biopharma ( NASDAQ: XERS ) shares gained ~4% premarket on Thursday after the biopharmaceutical company updated its outlook for full year 2022 . The firm expects to end 2022 with over $120M in cash, cash equivalents, and short-term investments and at the top of its net pr...

Company expects to end 2022 with over $120M in cash, cash equivalents, and short-term investments and at the top of its net product revenue guidance of $105M-$110M Company to report Q4 and FY 2022 financial results on or about March 8, 2023 Xeris Biopharma Holdings, Inc. (Nasdaq...